Results 111 to 120 of about 11,087,757 (202)

Progressive loss of glycemic control during chronic DPP-4 inhibitor therapy despite preserved β-cell function: a case report suggesting acquired incretin resistance. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Prasad S, Ahuja A, Sharma S, Nagda J, Agrawal S, Parmar V, Vardhan H.   +6 more
europepmc   +1 more source

Comment on "Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial". [PDF]

J Diabetes
Ayesha S, Parveen U, Irshad NUN.
europepmc   +1 more source

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19. [PDF]

Diabetes Metab J, 2021
Rhee SY, Lee J, Nam H, Kyoung DS, Shin DW, Kim DJ.   +5 more
europepmc   +1 more source

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

, 2010
Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1).
Ahren B, Bo Ahrén
core  

Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial. [PDF]

J Diabetes
Gao W, Chen D, He H, Jiang N, Chen L, Ran X.   +5 more
europepmc   +1 more source

Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies. [PDF]

J Clin Med
Alkhalifah SA, Alshahrani WA, Alshehri AM, Al Yami MS.   +3 more
europepmc   +1 more source

DPP-4 inhibitor linagliptin modulates myocardial metabolism in a model of coronary artery disease. [PDF]

JTCVS Open
Muir KC, Harris DD, Stone C, Kanuparthy M, Hamze J, Sellke FW.   +5 more
europepmc   +1 more source

Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer. [PDF]

Cancer Res Commun, 2021
Saito A, Kitayama J, Horie H, Koinuma K, Kawashima R, Ohzawa H, Yamaguchi H, Kawahira H, Mimura T, Lefor AK, Sata N.   +10 more
europepmc   +1 more source

Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report From Palestine. [PDF]

Case Rep Gastrointest Med
Nasser A, Ladadweh H, Madia R, Dalashi A, Wahdan A, Alawi A.   +5 more
europepmc   +1 more source

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. [PDF]

Lancet Diabetes Endocrinol, 2023
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J, DINAMO Study Group.   +8 more
europepmc   +1 more source